鉴于上述财务数据未经审计，公司提醒广大投资者注意投资风险。公司指定的信息披露媒体为《中国证 券报》《上海证券报》《证券时报》《证券日报》和巨潮资讯网（www.cninfo.com.cn），本公司所有 信息均以在上述选定媒体刊登的信息为准。 近日，公司计划处置的北陆药业部分股票已实施完毕，现将有关情况公告如下： 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重庆三峡油漆股份有限公司（以下简称"公司"）第十届董事会第二十四次会议审议通过了《关于拟处置 部分北陆药业股票的议案》，同意公司未来拟通过深圳证券交易所集中竞价交易方式、大宗交易方式或 两者相结合的方式，自北陆药业减持计划预披露公告之日起的15个交易日后的3个月内出售不超过1,000 万股公司持有的北京北陆药业股份有限公司（以下简称"北陆药业"，股票代码：300016）股票。具体内 容详见公司于2025年10月25日披露的《关于拟处置部分北陆药业股票的公告》（公告编号：2025- 062）。 公司于2025年11月17日至2025年12月31日处置北陆药业股 ...

Group 1 - The company announced a projected operating revenue of 287,684,655.66 yuan for 2025, representing a year-on-year growth of 6.37% [2] - The net profit attributable to shareholders of the listed company is expected to be 50,331,897.74 yuan in 2025, reflecting a year-on-year increase of 1.34% [2]

Group 1 - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue up to 94,936,708 A-shares to its controlling shareholder, Yangtze Industry Investment Group, raising a total of no more than 600 million RMB [1] - The purpose of the private placement is to repay company loans and supplement working capital, aiming to optimize capital structure and enhance financial stability [1] - As of September 2025, Guangji Pharmaceutical's debt-to-asset ratio is 62.67%, and the company has experienced continuous losses since 2023, with a projected net loss of between 399 million RMB and 518 million RMB for 2025 [1] Group 2 - The main reasons for the losses include long-term low prices in the vitamin B2 market and intense market competition, which have prevented sales prices from recovering [1] - The company believes that the private placement will enhance its risk resistance and reflects the controlling shareholder's confidence in the company's future development, which is beneficial for consolidating control [1] - The vitamin B2 market is expected to enter a phase of moderate growth starting in 2026 due to adjustments in market demand and opportunities for cost reduction from technological upgrades [1]

Suspension and Resumption - Huapei Power plans to issue convertible bonds and pay cash to acquire 100% equity of Meichuang Zhiguan, resulting in stock suspension [1] - Zhongnan Culture intends to purchase controlling stake in Sulong Thermal Power, leading to stock suspension [2] Private Placement and Mergers - Wenzhou Hongfeng aims to raise no more than 450 million yuan for lithium battery copper foil and electronic copper foil expansion projects, as well as semiconductor etching lead frame projects [3] - Jingrui Electric Materials plans to invest 600 million yuan to build a comprehensive base for key materials supporting the integrated circuit manufacturing industry chain in the western region [4] - Changling Hydraulic is undergoing a tender offer to acquire 12% of the company [5] - Fulongma intends to raise no more than 1.005 billion yuan for the construction of a smart sanitation operation service platform and a research center for unmanned sanitation equipment [5] - Xiamen Airport plans to acquire 100% equity of Zhaoxiang Technology for 1.193 billion yuan, focusing on civil aviation information, smart logistics, and low-carbon transformation [5] Equity Transfer and Buybacks - Gaole Co., Ltd. sees a change in control as Beijing Lieman Yuntu Technology Co., Ltd. acquires 10% of the company [6] - Quzhou Development's controlling shareholder proposes a buyback of 100 million to 200 million yuan [7] - Hongqi Chain's Shangtou Investment acquires 18% of the company's shares [8] - Huangshanghuang's Rongyue Chunhe Duxing Private Fund acquires 5.88% of the company's shares [9] External Investment and Daily Operations - Xiechuang Data plans to procure servers worth up to 11 billion yuan to provide cloud computing services for clients [10] - Penghui Energy intends to invest 1.2 billion yuan in the construction of a 587Ah and 120Ah battery production project [11] - Chengda Biology has received approval for clinical trials of a high-dose influenza virus split vaccine [12] - Teruid has pre-qualified for the China Resources New Energy Turpan Toksun 1 million kilowatt wind power project, with an expected bid amount of approximately 137 million yuan [13] - Jiuding New Materials is investing 201 million yuan in the "special glass fiber winding mat technology transformation project" [14] - Hanbo High-tech's subsidiary Xindongjin plans to acquire assets to enter the wet electronic chemicals industry [15] - Weitang Industrial has signed a strategic cooperation framework agreement with Amphenol [16] Performance Changes - Zhuozhao Dispensing expects a net profit of 260,000 yuan in 2025, a year-on-year increase of 350.08%, with revenue exceeding 10 million yuan through indirect supply of precision dispensing valves to Meta [17]

Group 1 - The company has made progress in governance and financing, completing the non-trading transfer of 12 million shares at a price of 4.53 yuan per share, which accounts for 0.94% of the total share capital, with a duration of no more than 48 months and unlocking in two phases [1] - The company has received acceptance from the Shenzhen Stock Exchange for its application to issue convertible bonds to unspecified objects, and related work is progressing in an orderly manner [1] Group 2 - The stock price of the company has shown slight fluctuations, with a decrease of 0.38% from the closing price of 7.86 yuan on February 5 to 7.83 yuan on February 12, with a trading range of 2.42% [2] - The highest stock price during this period was 8.01 yuan on February 10, while the lowest was 7.82 yuan on February 12 [2] - The trading volume peaked at a turnover rate of 1.48% on February 6, but decreased to 0.59% on February 12, with a transaction amount shrinking to 43.49 million yuan [2] - The stock price is currently below the 20-day moving average of 8.02 yuan, and the MACD indicator shows a weak consolidation trend [2]

Core Viewpoint - Chengyi Pharmaceutical (603811) announced that four of its products have been selected for the national centralized procurement program, with a procurement period extending to December 31, 2028, covering nationwide regions [1] Group 1: Product Details - The four selected products include Glucosamine Hydrochloride Capsules, Torasemide Injection, Lidocaine Hydrochloride Injection, and L-Carnitine Injection, each targeting specific medical conditions such as osteoarthritis, heart failure, local anesthesia, and complications from chronic kidney disease [1] - Glucosamine Hydrochloride Capsules are indicated for the treatment and prevention of osteoarthritis, with selected specifications of 750mg in 120 capsules and 750mg in 60 capsules [1] - Torasemide Injection is aimed at patients with edema due to congestive heart failure and liver cirrhosis, with selected specifications of 2ml:10mg in 10 vials and 4ml:20mg in 5 vials [1] - Lidocaine Hydrochloride Injection serves as a local anesthetic and antiarrhythmic agent, with a selected specification of 5ml:0.1g in 5 vials [1] - L-Carnitine Injection is for patients with chronic kidney disease undergoing long-term dialysis, with selected specifications of 5ml:1g in 5 vials and 5ml:2g in 5 vials [1] Group 2: Revenue Contribution - Among the four products, Glucosamine Hydrochloride Capsules are the core product, contributing significantly to revenue, with projected sales of 334.89 million yuan in 2024, accounting for 46.88% of the company's total revenue for that year [2] - For the first three quarters of 2025, the revenue from Glucosamine Hydrochloride Capsules is expected to reach 345.37 million yuan, representing 57.85% of the company's revenue during that period [2] - The other three products have relatively smaller revenue contributions, with Torasemide Injection generating 6.55 million yuan in 2024 and 4.20 million yuan in the first three quarters of 2025, accounting for 0.92% and 0.70% of total revenue, respectively [2] - Lidocaine Hydrochloride Injection and L-Carnitine Injection have minimal revenue, with figures below 0.1% for the respective periods [2] Group 3: Procurement Process - The centralized procurement process involves a coalition of provinces and regions across the country, led by Jiangsu, Henan, and Guangdong provinces to conduct unified procurement [3] - During the procurement period, medical institutions will prioritize the use of the selected drugs and ensure the completion of the agreed procurement volume [3] - Any remaining procurement volume after calculating the volume-based ratio can be selected from other companies that meet the bidding criteria [3]

Core Viewpoint - The company announced the conclusion of certain fundraising projects and the permanent allocation of surplus funds to working capital [1] Group 1: Project Conclusion - The company held its third board meeting on February 12, 2026, where it approved the conclusion of specific fundraising projects [1] - The projects concluded include the "Phase III clinical and post-marketing research project for Aibond® (Ainovelin tablets)" and the "Phase III/IV clinical project for ACC008" [1] - Both projects have reached the predetermined usable status as of the conclusion date [1] Group 2: Financial Details - As of December 31, 2025, the total surplus fundraising amount from the concluded projects is 36.4993 million yuan [1] - The company plans to permanently allocate the surplus funds to working capital [1] - Following the transfer of surplus funds, the company will cancel the corresponding fundraising special account [1]

Core Viewpoint - The approval of the abbreviated new drug application for Acetate Glatiramer Injection by the U.S. FDA marks a significant milestone for the company, enhancing its product pipeline and market presence in the U.S. [1] Group 1: Product Information - Acetate Glatiramer is an immunomodulatory drug used for treating relapsing forms of multiple sclerosis (MS) [1] - The drug mimics the structure of myelin basic protein to regulate abnormal autoimmune responses, thereby reducing attacks on the central nervous system's myelin [1] - It is effective in lowering relapse frequency and delaying disease progression, suitable for patients with clinical isolated syndrome and relapsing-remitting multiple sclerosis [1] Group 2: Market Impact - The approval will enrich the company's overseas product pipeline and broaden its pharmaceutical market in the U.S. [1] - The company plans to actively promote the sales of this drug in overseas markets, which is expected to positively impact future performance and industry standing [1]

Core Viewpoint - The company, Yabont Chemical (300261.SZ), clarifies that it does not produce niacinamide and focuses on CDMO services for innovative pharmaceuticals and agricultural intermediates [1] Group 1 - The company's NMN-related business is operating normally [1] - The overseas subsidiary organizes and commissions compliant foreign manufacturers for production [1] - Products are sold through cross-border e-commerce platforms such as JD International and Pinduoduo [1]

Core Viewpoint - The company, Yabao Chemical (300261.SZ), clarifies that it does not produce niacinamide and focuses on CDMO services for innovative pharmaceuticals and agricultural intermediates [1] Group 1: Business Operations - The company's NMN-related business is operating normally, organized by its overseas subsidiary [1] - Production is entrusted to compliant overseas manufacturers [1] - Sales are conducted through cross-border e-commerce platforms such as JD International and Pinduoduo [1]